| Literature DB >> 28290501 |
Shaoyong Ke1, Liqiao Shi1, Zhigang Zhang1, Ziwen Yang1.
Abstract
A series of steroidal[17,16-d]pyrimidines derived from dehydroepiandrosterone were designed and prepared by a convenient heterocyclization reaction. The in vitro anticancer activities for these obtained compounds were evaluated against human cancer cell lines (HepG2, Huh-7, and SGC-7901), which demonstrated that some of these heterocyclic pyrimidine derivatives exhibited significantly good cytotoxic activities against all tested cell lines compared with 5-fluorouracil (5-FU), especially, compound 3b exhibited high potential growth inhibitory activities against all tested cell lines with the IC50 values of 5.41 ± 1.34, 5.65 ± 1.02 and 10.64 ± 1.49 μM, respectively, which might be used as promising lead scaffold for discovery of novel anticancer agents.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28290501 PMCID: PMC5349525 DOI: 10.1038/srep44439
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Representative structures for several pyrimidine derivatives.
Figure 2Design strategy of steroidal[17,16-d]pyrimidines.
Figure 3Synthesis of steroidal[17,16-d]pyrimidines derivatives.
Figure 4Representative 1H NMR spectra for compound 3a.
Figure 5Antitumor activities of compounds 2a-p and 3a-p at 40 μg/mL.
Cytotoxic activity of the steroidal derivatives.
| Entry | Compd.No. | Substrates (R) | |||
|---|---|---|---|---|---|
| HepG2 | Huh-7 | SGC-7901 | |||
| 1 | Ph | 31.74 ± 6.11 | 29.24 ± 5.66 | 31.66 ± 7.71 | |
| 2 | 2-ClPh | 29.21 ± 2.78 | 27.67 ± 3.71 | 27.04 ± 4.58 | |
| 3 | 4-ClPh | >95 | >95 | >95 | |
| 4 | 2-FPh | 35.24 ± 3.96 | 29.60 ± 7.00 | 30.04 ± 5.18 | |
| 5 | 4-FPh | >100 | >100 | >100 | |
| 6 | 2-CF3Ph | 24.09 ± 4.91 | 18.30 ± 2.14 | 21.63 ± 3.31 | |
| 7 | 4-CF3Ph | >90 | >90 | >90 | |
| 8 | 2,4-Cl2Ph | 33.50 ± 3.44 | 27.17 ± 5.72 | 25.06 ± 5.07 | |
| 9 | 2-F-4-BrPh | 72.21 ± 9.40 | 50.88 ± 9.64 | 34.25 ± 6.10 | |
| 10 | 4-CH3OPh | >95 | >95 | >95 | |
| 11 | 4-CH3SPh | >90 | >90 | >90 | |
| 12 | 3,4,5-(CH3O)3Ph | 16.68 ± 2.55 | 15.93 ± 3.28 | 18.85 ± 3.43 | |
| 13 | 2-Py | >100 | >100 | >100 | |
| 14 | 3-Py | >100 | >100 | >100 | |
| 15 | 4-Py | >100 | >100 | >100 | |
| 16 | 3-PhOPh | >85 | >85 | >85 | |
| 17 | Ph | 17.94 ± 2.19 | 12.98 ± 3.25 | 20.49 ± 3.76 | |
| 18 | 2-ClPh | 5.41 ± 1.34 | 5.65 ± 1.02 | 10.64 ± 1.49 | |
| 19 | 4-ClPh | >85 | >85 | >85 | |
| 20 | 2-FPh | 9.58 ± 3.60 | 12.53 ± 2.05 | 17.33 ± 2.61 | |
| 21 | 4-FPh | 16.80 ± 2.91 | 21.92 ± 1.96 | 23.61 ± 3.05 | |
| 22 | 2-CF3Ph | 11.18 ± 2.46 | 13.87 ± 2.26 | 14.88 ± 1.53 | |
| 23 | 4-CF3Ph | 12.17 ± 3.91 | 7.43 ± 1.39 | 11.11 ± 0.83 | |
| 24 | 2,4-Cl2Ph | 15.34 ± 3.33 | 6.02 ± 0.25 | 13.35 ± 3.52 | |
| 25 | 2-F-4-BrPh | 14.77 ± 4.52 | 8.69 ± 1.21 | 18.88 ± 3.36 | |
| 26 | 4-CH3OPh | 19.60 ± 5.17 | 20.57 ± 5.75 | 25.71 ± 2.07 | |
| 27 | 4-CH3SPh | 20.42 ± 2.86 | 22.85 ± 6.42 | 24.67 ± 4.49 | |
| 28 | 3,4,5-(CH3O)3Ph | 6.59 ± 1.78 | 5.38 ± 1.84 | 15.71 ± 2.34 | |
| 29 | 2-Py | 84.48 ± 6.77 | >95 | >95 | |
| 30 | 3-Py | 22.84 ± 5.09 | 25.10 ± 6.87 | 33.97 ± 6.44 | |
| 31 | 4-Py | 29.86 ± 7.30 | 35.34 ± 10.09 | 60.77 ± 2.67 | |
| 32 | 3-PhOPh | 32.33 ± 6.86 | >75 | 40.63 ± 2.23 | |
| 33 | — | 39.04 ± 10.26 | >100 | >95 | |
| 34 | — | >100 | >95 | >100 | |
aIC50 – Compound concentration required to inhibit tumor cell proliferation by 50%.
bAbbreviations: HepG2 – Human hepatocellular liver carcinoma cell line; Huh-7 – Human hepatoma cell line; SGC-7901 – Human gastric cancer cell line.
cDHEA – Dehydroepiandrosterone.
d5-Fluorouracil, used as a positive control.
Figure 6Dose-response analysis of cell growth inhibition activity for the potential compounds 3b, 3d, 3g, 3l and 5-FU (positive control) against HepG2 (A), Huh-7 (B), and SGC-7901 (C) cell lines.
Figure 7General structure-activity profile for these steroidal derivatives.